Dual Biological Therapy for Ulcerative Colitis with Intractable Pyoderma Gangrenosum
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Pyoderma gangrenosum is one of the dermatological extra-intestinal manifestations of ul- cerative colitis (UC). We report a case of a 26-year-old male patient suffering from relapsed UC with a newly developed pyoderma gangrenosum. His skin and intestinal symptoms were intractable to treatment with steroids, immunosuppressants, or a single biological agent such as inf liximab, golimumab, or vedolizumab. For the first time in Korea, we report a successful treatment experience of pyoderma gangrenosum in UC using dual biological agents, vedolizumab and inf liximab. We strategically targeted each of the intestinal and skin symptoms, with a specific biological agent based on the drug’s mechanism of action.
Abstract
Pyoderma gangrenosum is one of the dermatological extra-intestinal manifestations of ul- cerative colitis (UC). We report a case of a 26-year-old male patient suffering from relapsed UC with a newly developed pyoderma gangrenosum. His skin and intestinal symptoms were intractable to treatment with steroids, immunosuppressants, or a single biological agent such as inf liximab, golimumab, or vedolizumab. For the first time in Korea, we report a successful treatment experience of pyoderma gangrenosum in UC using dual biological agents, vedolizumab and inf liximab. We strategically targeted each of the intestinal and skin symptoms, with a specific biological agent based on the drug’s mechanism of action.
참고문헌 (19)
- Ermis F, "Pyoderma gangrenosum treated with infliximab in inactive ulcerative colitis", Inflamm Bowel Dis, 14, pp.1611~1613 (2008)
- Fernández A, "Response to infliximab in atypical pyoderma gangrenosum associated with ulcerative colitis", Am J Gastroenterol, 103, pp.2951~2952 (2008)
- Molnar T, "Successful use of infliximab for treating fistulizing pouchitis with severe extraintestinal manifestation : a case report", Inflamm Bowel Dis, 14, pp.1752~1753 (2008)
- Colombel JF, "The safety of vedolizumab for ulcerative colitis and Crohn’s disease", Gut, 66, pp.839~851 (2017)
- Feagan BG, "Vedolizumab as induction and maintenance therapy for ulcerative colitis", N Engl J Med, 369, pp.699~710 (2013)
- Sandborn WJ, "Vedolizumab as induction and maintenance therapy for Crohn’s disease", N Engl J Med, 369, pp.711~721 (2013)
- Chateau T, "Vedolizumab treatment in extra-intestinal manifestations in inflammatory bowel disease : a systematic review", J Crohns Colitis, 13, pp.1569~1577 (2019)
- Reguiaï Z, "The role of anti-tumor necrosis factor-alpha therapy in pyoderma gangrenosum associated with inflammatory bowel disease", Am J Clin Dermatol, 8, pp.67~77 (2007)
- Teagle A, "Management of pyoderma gangrenosum", J R Soc Med, 107, pp.228~236 (2014)
- Thakur N, "Leukocyte adhesion defect type 1 presenting with recurrent pyoderma gangrenosum", Indian J Dermatol, 58, pp.158~ (2013)
- Groudan K, "Vedolizumab(Entyvio®)for the treatment of pyoderma gangrenosum in a Crohn’s disease patient", Cureus, 13, pp.e12582~ (2021)
- Koduru P, "Resolution of pyoderma gangrenosum with Vedolizumab in a Crohn’s patient : 2017 presidential poster award 1973", Am J Gastroenterol, 112, pp.S1091~ (2017)
- Peyrin-Biroulet L, "Systematic review of tumor necrosis factor antagonists in extraintestinal manifestations in inflammatory bowel disease", Clin Gastroenterol Hepatol, 15, pp.25~36 (2017)
- Regueiro M, "Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease", Am J Gastroenterol, 98, pp.1821~1826 (2003)
- Argüelles-Arias F, "Characteristics and treatment of pyoderma gangrenosum in inflammatory bowel disease", Dig Dis Sci, 58, pp.2949~2954 (2013)
- Brooklyn TN, "Infliximab for the treatment of pyoderma gangrenosum : a randomised, double blind, placebo controlled trial", Gut, 55, pp.505~509 (2006)
- Diotallevi F, "Pyoderma gangrenosum successfully treated with golimumab : case report and review of the literature", Dermatol Ther, 32, pp.e12928~ (2019)
- Olbjørn C, "Combination of biological agents in moderate to severe pediatric inflammatory bowel disease : a case series and review of the literature", Paediatr Drugs, 22, pp.409~416 (2020)
- Ribaldone DG, "Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease : a systematic review with pool analysis", Scand J Gastroenterol, 54, pp.407~413 (2019)